Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Patient Name
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Integration of Ayurvedic formulations with iron folic acid in the treatment of nutritional anaemia among school going adolescents of Dehradun District
This study evaluated the effect of Ayurvedic preparations Sootshekhar Rasa (SR) and Sitopaladi Churna (SC) with iron and folic acid (IFA) on nutritional anaemia in 820 adolescents in Dehradun, India. After 90 days of treatment, all groups showed increased haemoglobin levels, with the best results in the group receiving SR + SC + IFA. No major side effects were reported, and the treatment led to sustainable improvements in anaemia.
Acute and Sub acute Toxicity Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
This study tested the safety of five Ayurvedic formulations for migraine prevention in rats and mice. Acute and sub-acute toxicity studies showed no toxic effects at doses up to 10 times the human dose. A slight mortality in high-dose groups was unrelated to treatment. The formulations are considered safe, but further chronic toxicity studies are needed.
Randomized Controlled Study to Evaluate Prophylactic Properties of Ayurvedic Treatment Protocol in Refractory and Chronic Migraine Patients
This study compared Ayurvedic treatment to conventional therapy for chronic refractory migraine. After 360 days, the Ayurvedic group showed greater reductions in headache days, VAS, and MIDAS scores (p
Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up
A 47-year-old diabetic male with high-risk AML-M3 relapsed after multiple chemotherapy treatments. In 1997, he opted for a pilot Ayurvedic study and was treated with Navajeevan, Kamadudha Rasa, and Keharuba Pisti. He achieved complete remission and has remained disease-free for 13 years without side effects from the alternative treatment.
Symptom-free status after prolonged suffering with refractory chronic migraine: A case report
A 37-year chronic refractory migraine sufferer experienced significant relief in pain, symptoms, and overall well-being after nine months of Ayurvedic treatment, highlighting its potential therapeutic benefits.
Ayurvedic treatment protocol in the management of pancreatitis: A nonrandomized observational study
A North Indian clinic treated 1750 recurrent pancreatitis patients (1997–2023) with an ayurvedic Herbo-Mineral Formulation (HMF). Among 916 completing 1-year treatment, attacks reduced by 93%, hospitalizations by 97%, with no adverse effects. Long-term remission supports further clinical trials.